Heather Hitesman
Acute Care · Davenport, IANPI 1992259642
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $886 and has fallen 63.5% since, to $323 in 2025.
Across 100 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$392
- Axsome Therapeutics, Inc.$230
- Novartis$164
- Biogen$107
- Neurocrine Biosciences, Inc.$78
- Pfizer$76
- plus $848 from 28 others
What the payments were for
- Food & beverage$1,86698%
- Education$302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $392 |
| Axsome Therapeutics, Inc. | 14 | $230 |
| Novartis | 9 | $164 |
| Biogen | 4 | $107 |
| Neurocrine Biosciences, Inc. | 4 | $78 |
| Pfizer | 4 | $76 |
| Amneal Pharmaceuticals LLC | 3 | $68 |
| Inspire Medical Systems, Inc. | 2 | $68 |
| Neurelis, Inc. | 3 | $64 |
| Eisai Inc. | 3 | $60 |
| AstraZeneca(2 entities) | 2 | $39 |
| Lundbeck LLC | 2 | $36 |
| Amgen | 2 | $34 |
| Impel Pharmaceuticals Inc. | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| MDD US Operations, LLC | 1 | $32 |
| Genentech USA, Inc. | 3 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Argenx US, Inc. | 1 | $24 |
| Almatica Pharma LLC | 1 | $24 |
| SK Life Science, Inc. | 1 | $21 |
| Harmony Biosciences LLC | 1 | $20 |
| GE HealthCare | 1 | $20 |
| TG Therapeutics, Inc. | 1 | $20 |
| CSL Behring | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| UCB, Inc. | 1 | $16 |
| Abbott | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
How this compares
$1,895 in reported general payments places this provider in the 85th percentile of 104 acute care providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 42 | $39,850 |
| UbrelvyUbrogepant | 28 | $38,352 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 34 | $25,387 |
| Emgality PenGalcanezumab-Gnlm | 31 | $23,279 |
| Nurtec OdtRimegepant Sulfate | 18 | $18,135 |
| Lacosamide | 74 | $9,741 |
| Ajovy SyringeFremanezumab-Vfrm | 12 | $9,099 |
| Levetiracetam | 213 | $8,948 |
| BelsomraSuvorexant | 15 | $7,335 |
| Pregabalin | 201 | $6,600 |
| Gabapentin | 222 | $4,211 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 58 | $3,890 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 167 | $3,593 |
| Rivastigmine | 31 | $3,480 |
| Pyridostigmine Bromide | 15 | $2,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $392 | $38,35228 claims |
| PfizerNurtec Odt | $76 | $18,13518 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $68 | $2,72215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 104 acute care providers in Iowa.
Other acute care in Davenport
- Jessica WitterDavenport$5K
- Teri DevineDavenport$4K
- Shawna DuskeDavenport$2K
- Cheryl EhrlerDavenport$2K
- Gina ZelleDavenport$1K
- Cynthia BurkholderDavenport$1K
- Michelle LakeDavenport$1K
- Lori SchwarmDavenport$1K
- Abby ShumateDavenport$809
- Emily MaiersDavenport$627
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.